{
    "Trade/Device Name(s)": [
        "Prosigna Breast Cancer Prognostic Gene Signature Assay",
        "Prosigna\u2122 Breast Cancer Prognostic Gene Signature Assay"
    ],
    "Submitter Information": "Nanostring Technologies, Inc.",
    "510(k) Number": "K141771",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130010"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "May 28, 2015",
    "Summary Letter Received Date": "July 1, 2014",
    "Submission Date": "June 30, 2014",
    "Regulation Number(s)": [
        "21CFR866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "58 gene RNA expression profile"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NanoString nCounter Dx Analysis System",
        "Prep Station",
        "Digital Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Non-amplified RNA hybridization",
        "Multiplexed gene expression measurement",
        "Nucleic acid hybridization",
        "Fluorescent probe-based detection"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "RNA hybridization",
        "Image analysis",
        "Digital quantification"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Instrument",
        "Software",
        "Cartridge",
        "Prep Plate"
    ],
    "Document Summary": "FDA 510(k) summary for Prosigna gene signature assay for breast cancer prognosis using multiplexed gene expression profiling on the NanoString nCounter Dx Analysis System",
    "Indications for Use Summary": "Qualitative gene expression assay for prognosis of distant recurrence-free survival at 10 years in postmenopausal women with hormone receptor-positive breast cancer (Stage I/II, node-negative or 1-3 positive nodes), performed on FFPE breast tumor tissue, to aid risk assessment for adjuvant endocrine therapy decision-making",
    "fda_folder": "Immunology"
}